prednisone has been researched along with Anaplastic Large-Cell Lymphoma in 87 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Prior to overt cerebral invasion by NHL, she had a thiamine deficiency with very low thiamine concentrations in the CSF, probably caused by protracted vomiting and increased vitamin B1 consumption by intrathecal tumor cells." | 3.70 | Downbeat nystagmus caused by thiamine deficiency: an unusual presentation of CNS localization of large cell anaplastic CD 30-positive non-Hodgkin's lymphoma. ( Boerman, RH; Mattijssen, V; Mulder, AH; Raemaekers, JM, 1999) |
| "The index patient and second patient were diagnosed as having Ki-1-positive anaplastic large-cell lymphoma by immunophenotyping and underwent cyclophosphamide, doxorubicin, prednisone, and vincristine (CHOP) chemotherapy with complete remission." | 3.68 | Ki-1-positive anaplastic large-cell lymphoma can mimic benign dermatoses. ( Camisa, C; Helm, TN; Sexton, C; Tuthill, R, 1993) |
| "Then lenalidomide was performed as a maintenance therapy." | 1.56 | Synchronous diagnosis of anaplastic large cell lymphoma and multiple myeloma in a patient: A case report. ( Chen, M; Chen, W; Jiang, Q; Li, T; Liu, Y; Peng, J; Shi, X; Wu, J; Xi, X; Yu, X; Zhang, S; Zhu, Y, 2020) |
| "Fibrosing mediastinitis is rare." | 1.39 | Anaplastic large cell lymphoma mimicking fibrosing mediastinitis. ( Amitani, R; Ariyasu, R; Hanaoka, K; Inada, S; Konishi, Y; Nagano, H; Nakagawa, K; Nakamura, Y; Nishizaka, Y; Okamoto, N; Taki, M; Tsudo, M; Wakasa, T; Wakayama, T; Yoshida, M; Yoshimura, C, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 18 (20.69) | 18.2507 |
| 2000's | 20 (22.99) | 29.6817 |
| 2010's | 41 (47.13) | 24.3611 |
| 2020's | 8 (9.20) | 2.80 |
| Authors | Studies |
|---|---|
| Savage, KJ | 3 |
| Horwitz, SM | 1 |
| Advani, R | 1 |
| Christensen, JH | 1 |
| Domingo-Domenech, E | 1 |
| Rossi, G | 1 |
| Morschhauser, F | 1 |
| Alpdogan, O | 1 |
| Suh, C | 1 |
| Tobinai, K | 1 |
| Shustov, A | 1 |
| Trneny, M | 2 |
| Yuen, S | 1 |
| Zinzani, PL | 3 |
| Trümper, L | 1 |
| Ilidge, T | 1 |
| O'Connor, OA | 1 |
| Pro, B | 1 |
| Miao, H | 1 |
| Bunn, V | 1 |
| Fenton, K | 1 |
| Fanale, M | 1 |
| Puhlmann, M | 1 |
| Iyer, S | 1 |
| Brink, M | 1 |
| Meeuwes, FO | 1 |
| van der Poel, MWM | 1 |
| Kersten, MJ | 1 |
| Wondergem, M | 1 |
| Mutsaers, PGNJ | 1 |
| Böhmer, LH | 1 |
| Woei-A-Jin, FJSH | 1 |
| Visser, O | 1 |
| Oostvogels, R | 1 |
| Jansen, PM | 1 |
| Plattel, W | 1 |
| Huls, GA | 1 |
| Vermaat, JSP | 1 |
| Nijland, M | 1 |
| Ludvigsen Al-Mashhadi, A | 1 |
| Cederleuf, H | 1 |
| Kuhr Jensen, R | 1 |
| Holm Nielsen, T | 1 |
| Bjerregård Pedersen, M | 1 |
| Bech Mortensen, T | 1 |
| Relander, T | 1 |
| Jerkeman, M | 1 |
| Ortved Gang, A | 1 |
| Kristensen, AL | 1 |
| Roost Clausen, M | 1 |
| de Nully Brown, P | 1 |
| Tang Severinsen, M | 1 |
| Jakobsen, LH | 1 |
| Ellin, F | 1 |
| El-Galaly, TC | 1 |
| Karube, K | 1 |
| Feldman, AL | 2 |
| Chen, YK | 1 |
| Yu, WJ | 1 |
| Liu, H | 1 |
| Wei, JY | 1 |
| Qian, WB | 1 |
| Jin, J | 2 |
| Luo, DX | 1 |
| Li, W | 1 |
| Ye, MT | 1 |
| Yang, Y | 1 |
| Tang, G | 1 |
| You, MJ | 1 |
| Shi, X | 1 |
| Wu, J | 1 |
| Jiang, Q | 1 |
| Zhang, S | 1 |
| Chen, W | 1 |
| Yu, X | 1 |
| Liu, Y | 3 |
| Chen, M | 1 |
| Peng, J | 1 |
| Li, T | 1 |
| Zhu, Y | 1 |
| Xi, X | 1 |
| Calleja, A | 1 |
| Bouclet, F | 1 |
| Morel, A | 1 |
| Brière, J | 2 |
| Lamant, L | 2 |
| Loschi, M | 1 |
| Haioun, C | 1 |
| Delarue, R | 1 |
| Tournilhac, O | 1 |
| Bachy, E | 1 |
| Sonet, A | 1 |
| Amorim, S | 1 |
| Laurent, C | 1 |
| Gaulard, P | 2 |
| Tilly, H | 2 |
| Sibon, D | 2 |
| Patzelt, M | 1 |
| Zarubova, L | 1 |
| Klener, P | 1 |
| Barta, J | 1 |
| Benkova, K | 1 |
| Brandejsova, A | 1 |
| Gürlich, R | 1 |
| Sukop, A | 1 |
| Elswick, SM | 1 |
| Nguyen, MT | 1 |
| Dong, F | 1 |
| Li, Q | 1 |
| Wang, J | 2 |
| Jing, H | 1 |
| Ke, X | 1 |
| Amante, MA | 1 |
| Galagnara, SJP | 1 |
| Ignacio, J | 1 |
| Kawamoto, K | 1 |
| Suzuki, T | 1 |
| Kasami, T | 1 |
| Kiryu, M | 1 |
| Sone, H | 1 |
| Miyoshi, H | 1 |
| Ohshima, K | 1 |
| Takizawa, J | 1 |
| Nguyen, DP | 1 |
| Schmitz, N | 2 |
| Suzuki, R | 1 |
| Gressin, R | 1 |
| Weisenburger, DD | 1 |
| Rosenwald, A | 1 |
| Nakamura, S | 1 |
| Ziepert, M | 1 |
| Maurer, MJ | 1 |
| Bast, M | 1 |
| Armitage, JO | 1 |
| Vose, JM | 1 |
| Jais, JP | 1 |
| Kim, MK | 1 |
| Cho, CH | 1 |
| Sung, WJ | 1 |
| Ryoo, HM | 1 |
| Lee, HJ | 1 |
| Youn, SW | 1 |
| Park, KK | 1 |
| Taki, M | 1 |
| Inada, S | 1 |
| Ariyasu, R | 1 |
| Konishi, Y | 1 |
| Okamoto, N | 1 |
| Yoshida, M | 1 |
| Nagano, H | 1 |
| Hanaoka, K | 1 |
| Nakagawa, K | 1 |
| Nakamura, Y | 1 |
| Yoshimura, C | 1 |
| Wakayama, T | 1 |
| Nishizaka, Y | 1 |
| Wakasa, T | 1 |
| Tsudo, M | 1 |
| Amitani, R | 1 |
| Ok, CY | 1 |
| Wang, SA | 1 |
| Amin, HM | 1 |
| Alexander, S | 1 |
| Kraveka, JM | 1 |
| Weitzman, S | 2 |
| Lowe, E | 1 |
| Smith, L | 1 |
| Lynch, JC | 1 |
| Chang, M | 1 |
| Kinney, MC | 1 |
| Perkins, SL | 1 |
| Laver, J | 1 |
| Gross, TG | 1 |
| Weinstein, H | 1 |
| Yu, L | 1 |
| Yan, LL | 1 |
| Yang, SJ | 1 |
| Yu, G | 1 |
| Gao, Z | 1 |
| Huang, X | 1 |
| Hwang, MJ | 1 |
| Brown, H | 1 |
| Murrin, R | 1 |
| Momtahan, N | 1 |
| Sterne, GD | 1 |
| Kwok, C | 1 |
| Salmo, E | 1 |
| Dion, GR | 1 |
| Packer, MD | 1 |
| Al-Asaadi, Z | 1 |
| Fatin, S | 1 |
| Patel, K | 1 |
| Chetty, N | 1 |
| Dubrey, S | 1 |
| Dunleavy, K | 1 |
| Pittaluga, S | 1 |
| Shovlin, M | 1 |
| Roschewski, M | 1 |
| Lai, C | 1 |
| Steinberg, SM | 1 |
| Jaffe, ES | 1 |
| Wilson, WH | 1 |
| Zhao, Q | 1 |
| Chen, H | 1 |
| Zhang, Y | 1 |
| Du, Z | 1 |
| Wang, Y | 3 |
| Ramos-Gallardo, G | 1 |
| Cuenca-Pardo, J | 1 |
| Rodríguez-Olivares, E | 1 |
| Iribarren-Moreno, R | 1 |
| Contreras-Bulnes, L | 1 |
| Vallarta-Rodríguez, A | 1 |
| Kalixto-Sanchez, M | 1 |
| Hernández, C | 1 |
| Ceja-Martinez, R | 1 |
| Torres-Rivero, C | 1 |
| Kim, KH | 1 |
| Jung, YH | 1 |
| Han, CW | 1 |
| Woo, IS | 1 |
| Son, JH | 1 |
| Tuck, M | 1 |
| Lim, J | 1 |
| Lucar, J | 1 |
| Benator, D | 1 |
| Olin, RL | 1 |
| Nichols, KE | 1 |
| Naghashpour, M | 1 |
| Wasik, M | 1 |
| Shelly, B | 1 |
| Stadtmauer, EA | 1 |
| Vogl, DT | 1 |
| Ziarkiewicz-Wróblewska, B | 1 |
| Górnicka, B | 1 |
| Gierej, B | 1 |
| Suleiman, W | 1 |
| Nowacka-Cieciura, E | 1 |
| Durlik, M | 1 |
| Bogdańska, M | 1 |
| Wasiutyński, A | 1 |
| Pileri, SA | 4 |
| Vinogradova, IuE | 1 |
| Lutsenko, IN | 1 |
| Kaplanskaia, IB | 1 |
| Vorob'ev, IA | 1 |
| Samoĭlova, RS | 1 |
| Gorgidze, LA | 1 |
| Ryzhikova, NA | 1 |
| Valiev, TT | 1 |
| Giliazitdinova, EA | 1 |
| Dzhulakian, UL | 1 |
| Egorova, EK | 1 |
| Zvonkov, EE | 1 |
| Krasil'nikova, BB | 1 |
| Magomedova, AU | 1 |
| Margolin, OV | 1 |
| Mar'in, DS | 1 |
| Kremenetskaia, AM | 1 |
| Kravchenko, SK | 1 |
| Vorob'ev, AI | 1 |
| Azhir, A | 1 |
| Reisi, N | 1 |
| Taheri, D | 1 |
| Adibi, A | 1 |
| Chong, AL | 1 |
| Ngan, BY | 1 |
| Abla, O | 1 |
| Zeynalova, S | 1 |
| Loeffler, M | 1 |
| Pfreundschuh, M | 1 |
| Youd, E | 1 |
| Boyde, AM | 1 |
| Attanoos, RL | 1 |
| Dojcinov, SD | 1 |
| Balachandran, I | 1 |
| Walker, JW | 1 |
| Broman, J | 1 |
| Zhu, J | 1 |
| Song, YQ | 1 |
| Wang, L | 1 |
| Li, C | 1 |
| Gao, T | 1 |
| Wu, N | 1 |
| Pang, L | 1 |
| Chen, Z | 1 |
| Ma, Q | 1 |
| Chen, G | 1 |
| Chen, J | 1 |
| Huang, J | 1 |
| Zhan, HQ | 1 |
| Li, XQ | 1 |
| Zhu, XZ | 1 |
| Do, V | 1 |
| Shifrin, DA | 1 |
| Oostendorp, L | 1 |
| Asano, H | 1 |
| Imai, Y | 1 |
| Ota, S | 1 |
| Yamamoto, G | 1 |
| Takahashi, T | 1 |
| Fukayama, M | 1 |
| Kurokawa, M | 1 |
| Xie, JJ | 1 |
| Zhou, ZQ | 1 |
| Li, Y | 1 |
| Zhang, RY | 1 |
| Ren, YB | 1 |
| Chen, B | 2 |
| Zhou, GY | 1 |
| Li, N | 1 |
| Ren, D | 1 |
| Lü, BB | 1 |
| Xie, JL | 1 |
| Zheng, XD | 1 |
| Gong, LP | 1 |
| Zhou, XG | 1 |
| Stern, CJ | 1 |
| Toledo, MG | 1 |
| Hale, LG | 1 |
| Gook, DA | 1 |
| Edgar, DH | 1 |
| Foyil, KV | 1 |
| Kennedy, DA | 1 |
| Grove, LE | 1 |
| Bartlett, NL | 1 |
| Cashen, AF | 1 |
| Ferreri, AJ | 1 |
| Govi, S | 1 |
| Halasz, LM | 1 |
| Jacene, HA | 1 |
| Catalano, PJ | 1 |
| Van den Abbeele, AD | 1 |
| Lacasce, A | 1 |
| Mauch, PM | 1 |
| Ng, AK | 1 |
| Gable, AD | 1 |
| Clark, SH | 1 |
| Magro, CM | 1 |
| Cerban, R | 1 |
| Gheorghe, L | 1 |
| Becheanu, G | 1 |
| Serban, V | 1 |
| Gheorghe, C | 1 |
| Ordemann, R | 1 |
| Stöhlmacher, J | 1 |
| Beuthien-Baumann, B | 1 |
| Platzek, I | 1 |
| van den Hoff, J | 1 |
| Kroschinsky, F | 1 |
| Middeke, JM | 1 |
| Platzbecker, U | 1 |
| Zietz, C | 1 |
| Bornhäuser, M | 1 |
| Ehninger, G | 1 |
| He, XH | 1 |
| Li, B | 1 |
| Zou, SM | 1 |
| Dong, M | 1 |
| Zhou, SY | 1 |
| Yang, JL | 1 |
| Xue, LY | 1 |
| Yang, S | 1 |
| Liu, P | 1 |
| Qin, Y | 1 |
| Zhang, CG | 1 |
| Han, XH | 1 |
| Shi, YK | 1 |
| Nassiri, M | 1 |
| Robertson, MJ | 1 |
| Hertzberg, L | 1 |
| Czader, MB | 1 |
| Li, XX | 1 |
| Sang, W | 1 |
| Zhang, W | 1 |
| Shi, XL | 1 |
| Gulinaer, A | 1 |
| Yang, WT | 1 |
| Zhang, XM | 1 |
| Li, YX | 1 |
| Wang, WH | 1 |
| Wang, SL | 1 |
| Liu, YP | 1 |
| Song, YW | 1 |
| Ren, H | 1 |
| Fang, H | 1 |
| Zhou, LQ | 1 |
| Qi, SN | 1 |
| Liu, QF | 1 |
| Lu, NN | 1 |
| Liu, XF | 1 |
| Yu, ZH | 1 |
| Dawn, G | 1 |
| Morrison, A | 1 |
| Morton, R | 1 |
| Bilsland, D | 1 |
| Jackson, R | 1 |
| Tronnier, M | 1 |
| Merz, H | 1 |
| Huang, Q | 1 |
| Chang, KL | 1 |
| Gaal, KK | 1 |
| Weiss, LM | 1 |
| Shehan, JM | 1 |
| Kalaaji, AN | 1 |
| Markovic, SN | 1 |
| Ahmed, I | 1 |
| Chen, CH | 1 |
| Chen, SW | 1 |
| Shen, WL | 1 |
| Chen, TY | 1 |
| Tsao, CJ | 1 |
| Huang, WT | 1 |
| Rehman, JU | 1 |
| Rao, TV | 1 |
| AlKindi, S | 1 |
| Dennison, D | 1 |
| Pathare, AV | 1 |
| Isogai, R | 1 |
| Fukao, M | 1 |
| Kawada, A | 1 |
| Mandal, S | 1 |
| Varma, K | 1 |
| Jain, S | 1 |
| Pileri, S | 1 |
| Bocchia, M | 2 |
| Baroni, CD | 1 |
| Martelli, M | 3 |
| Falini, B | 3 |
| Sabattini, E | 3 |
| Gherlinzoni, F | 3 |
| Amadori, S | 2 |
| Poggi, S | 1 |
| Mazza, P | 2 |
| Finlay, JL | 1 |
| Anderson, JR | 1 |
| Cecalupo, AJ | 1 |
| Hutchinson, RJ | 1 |
| Kadin, ME | 1 |
| Kjeldsberg, CR | 1 |
| Provisor, AJ | 1 |
| Woods, WG | 1 |
| Meadows, AT | 1 |
| Camisa, C | 1 |
| Helm, TN | 1 |
| Sexton, C | 1 |
| Tuthill, R | 1 |
| Rubie, H | 1 |
| Gladieff, L | 1 |
| Robert, A | 2 |
| Gaubert, I | 1 |
| Huguet, F | 1 |
| Rochaix, P | 1 |
| Pein, F | 1 |
| Michel, G | 1 |
| Hoerni, B | 1 |
| Sommelet, D | 1 |
| Schulte-Huermann, P | 1 |
| Zumdick, M | 1 |
| Ruzicka, T | 1 |
| Fanin, R | 3 |
| Silvestri, F | 3 |
| Geromin, A | 3 |
| Cerno, M | 3 |
| Infanti, L | 3 |
| Zaja, F | 3 |
| Barillari, G | 2 |
| Savignano, C | 2 |
| Rinaldi, C | 2 |
| Damiani, D | 3 |
| Buffoli, A | 1 |
| Biffoni, F | 1 |
| Baccarini, M | 1 |
| Bendandi, M | 2 |
| Martelli, MF | 1 |
| Mandelli, F | 2 |
| Tura, S | 2 |
| Wang, JC | 1 |
| Kim, DS | 1 |
| Goldberg, M | 1 |
| Veldman, W | 1 |
| van Beek, M | 1 |
| Keuning, JJ | 1 |
| Driessen, WM | 1 |
| Chou, WC | 1 |
| Su, IJ | 1 |
| Tien, HF | 1 |
| Liang, DC | 1 |
| Wang, CH | 1 |
| Chang, YC | 1 |
| Cheng, AL | 1 |
| Engelhard, M | 1 |
| Brittinger, G | 1 |
| Huhn, D | 1 |
| Gerhartz, HH | 1 |
| Meusers, P | 1 |
| Siegert, W | 1 |
| Thiel, E | 1 |
| Wilmanns, W | 1 |
| Aydemir, U | 1 |
| Bierwolf, S | 1 |
| Griesser, H | 1 |
| Tiemann, M | 1 |
| Lennert, K | 1 |
| Baccarani, M | 2 |
| Kubonishi, I | 1 |
| Bandobashi, K | 1 |
| Murata, N | 1 |
| Daibata, M | 1 |
| Ido, E | 1 |
| Sonobe, H | 1 |
| Ohtsuki, Y | 1 |
| Miyoshi, I | 1 |
| Magagnoli, M | 1 |
| Zaccaria, A | 1 |
| Ronconi, F | 1 |
| Cantonetti, M | 1 |
| Marra, R | 1 |
| Gobbi, M | 1 |
| Moretti, L | 1 |
| De Renzo, A | 1 |
| Pavone, E | 1 |
| Amendola, A | 1 |
| Brugières, L | 1 |
| Deley, MC | 1 |
| Pacquement, H | 1 |
| Meguerian-Bedoyan, Z | 1 |
| Terrier-Lacombe, MJ | 1 |
| Pondarré, C | 1 |
| Leverger, G | 1 |
| Devalck, C | 1 |
| Rodary, C | 1 |
| Delsol, G | 1 |
| Hartmann, O | 1 |
| Chim, CS | 1 |
| Chan, AC | 1 |
| Raymond, L | 1 |
| Mulder, AH | 1 |
| Raemaekers, JM | 1 |
| Boerman, RH | 1 |
| Mattijssen, V | 1 |
| Sperotto, A | 1 |
| Stocchi, R | 1 |
| Patriarca, F | 1 |
| Jhala, DN | 1 |
| Medeiros, LJ | 1 |
| Lopez-Terrada, D | 1 |
| Jhala, NC | 1 |
| Krishnan, B | 1 |
| Shahab, I | 1 |
| Cazals-Hatem, D | 1 |
| André, M | 1 |
| Mounier, N | 1 |
| Copin, MC | 1 |
| Divine, M | 1 |
| Berger, F | 1 |
| Bosly, A | 1 |
| Kerneis, Y | 1 |
| Quesnel, B | 1 |
| Diebold, J | 1 |
| Herrera, E | 1 |
| Gallardo, M | 1 |
| Bosch, R | 1 |
| Cabra, B | 1 |
| Aneri, V | 1 |
| Sánchez, P | 1 |
| Creager, AJ | 1 |
| Geisinger, KR | 1 |
| Bergman, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients With CD30-positive Mature T-cell Lymphomas[NCT01777152] | Phase 3 | 452 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| A Phase III Trial of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma (ALCL) With Standard APO (Doxorubicin, Prednisone, Vincristine) Versus Consolidation With a Regimen Including Vinblastine[NCT00059839] | Phase 3 | 129 participants (Actual) | Interventional | 2003-11-30 | Completed | ||
| Nivolumab With Standard of Care Chemotherapy for the First Line Treatment of Peripheral T Cell Lymphoma[NCT03586999] | Phase 1/Phase 2 | 18 participants (Actual) | Interventional | 2018-11-07 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The count of participants with CR per IRF following the completion of study treatment (at end of treatment or at the first assessment after the last dose of study treatment and prior to long-term follow-up) according to the Revised Response Criteria for Malignant Lymphoma. (NCT01777152)
Timeframe: Up to 8.34 months
| Intervention | Participants (Count of Participants) |
|---|---|
| A+CHP | 153 |
| CHOP | 126 |
The count of participants with CR or partial response (PR) per IRF following the completion of study treatment (at end of treatment or the first assessment after the last dose of study treatment and prior to long-term follow-up) according to the Revised Response Criteria for Malignant Lymphoma. (NCT01777152)
Timeframe: Up to 8.34 months
| Intervention | Participants (Count of Participants) |
|---|---|
| A+CHP | 188 |
| CHOP | 163 |
The time from randomization to death due to any cause. (NCT01777152)
Timeframe: Up to 90 months
| Intervention | Months (Median) |
|---|---|
| A+CHP | NA |
| CHOP | NA |
The time from the date of randomization to the date of first documentation of progressive disease (PD), death due to any cause, or receipt of subsequent anticancer chemotherapy to treat residual or progressive disease whichever occurred first. (NCT01777152)
Timeframe: Up to 60 months
| Intervention | months (Median) |
|---|---|
| A+CHP | 48.20 |
| CHOP | 20.80 |
The time from the date of randomization to the date of first documentation of progressive disease (PD), death due to any cause, or receipt of subsequent anticancer chemotherapy to treat residual or progressive disease whichever occurred first. (NCT01777152)
Timeframe: Up to 60 months
| Intervention | months (Median) |
|---|---|
| A+CHP | 55.66 |
| CHOP | 32.03 |
Any untoward medical occurrence in a clinical investigational participant administered a medicinal product which does not necessarily have a causal relationship with this treatment. (NCT01777152)
Timeframe: Up to 8.28 months
| Intervention | Participants (Count of Participants) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Any treatment-emergent AE | Blinded study treatment-related AE | CHP treatment-related AE | Any serious adverse event (SAE) | Blinded study treatment-related SAE | CHP treatment-related SAE | Treatment discontinuations due to AE | Treatment discontinuations due to blinded study treatment-related AE | Treatment discontinuations due to CHP treatment-related AE | |
| A+CHP | 221 | 201 | 198 | 87 | 58 | 62 | 14 | 10 | 8 |
| CHOP | 221 | 193 | 205 | 87 | 45 | 53 | 15 | 10 | 7 |
Number of participants who experienced a Grade 3 or higher laboratory toxicity. (NCT01777152)
Timeframe: Up to 8.28 months
| Intervention | Participants (Count of Participants) | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any Chemistry Test | Alanine Aminotransferase High | Albumin Low | Alkaline Phosphatase High | Calcium Low | Glucose High | Phosphate Low | Potassium High | Potassium Low | Sodium High | Sodium Low | Urate High | Any Hematology Test | Absolute Neutrophil Count Low | Hemoglobin High | Hemoglobin Low | Leukocytes Low | Lymphocytes High | Lymphocytes Low | Neutrophils Low | Platelets Low | |
| A+CHP | 25 | 3 | 2 | 1 | 1 | 8 | 4 | 0 | 3 | 1 | 4 | 5 | 68 | 17 | 1 | 9 | 12 | 0 | 52 | 17 | 1 |
| CHOP | 23 | 1 | 3 | 0 | 1 | 6 | 3 | 2 | 2 | 0 | 6 | 2 | 78 | 19 | 0 | 13 | 21 | 1 | 61 | 19 | 1 |
Percentage of EFS patients. This is measured as the time from study entry until disease progression, disease recurrence, occurrence of a second malignant neoplasm, or death from any cause. To measure Event Free Survival, repeated one-sided logrank tests will be performed The upper critical values are based on the one-sided alpha-spending functions of t2 (alpha=0.05) and the lower critical values are based on testing the alternative hypothesis at 0.005 level. (NCT00059839)
Timeframe: From first enrollment up to 3 years.
| Intervention | percentage of participants (Number) |
|---|---|
| Standard (APO) With Vincristine (Arm I) | 74 |
| Consolidation (Includes Vinblastine) (Arm II) | 79 |
13 reviews available for prednisone and Anaplastic Large-Cell Lymphoma
| Article | Year |
|---|---|
Sarcomatoid variant of ALK- anaplastic large cell lymphoma involving multiple lymph nodes and both lungs with production of proinflammatory cytokines: report of a case and review of literature.
Topics: Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclo | 2014 |
Breast implant-associated anaplastic large cell lymphoma: a case report and literature review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Implantation; Breast Implants | 2015 |
Successful Chemo-Radiotherapy for Primary Anaplastic Large Cell Lymphoma of the Lung: A Case Report and Literature Review.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cyclophosphamide; Doxorubi | 2016 |
Breast Implant and Anaplastic Large Cell Lymphoma Meta-Analysis.
Topics: Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breas | 2017 |
Hodgkin-like lymphoma, simulating anaplastic large cell lymphoma in the patient after renal transplantation--unusual case report and literature review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Biomarkers, Tumor; Bone Marrow; Cy | 2008 |
Primary esophageal CD30-positive ALK-positive anaplastic large cell lymphoma: a case report and literature review.
Topics: Adult; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; | 2011 |
[Recent advance in peripheral T-cell lymphoma, not otherwise specified].
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antige | 2010 |
Anaplastic large cell lymphoma, ALK-positive.
Topics: Anaplastic Lymphoma Kinase; Animals; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cycl | 2012 |
Myxoid variant of anaplastic large cell lymphoma involving the skin: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; CD4 Antigens; Combined Modality Therapy; Cyclophosph | 2012 |
Primary focal T-cell lymphoma of the liver: a case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cyclophosphamide; Doxorubicin; Etoposide; Hu | 2012 |
Primary effusion anaplastic large cell lymphoma in a patient with long-standing dermatitis herpetiformis and celiac disease.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Celiac Disease; Cyclophosphamide; Derm | 2013 |
Management of multifocal primary cutaneous CD30 anaplastic large cell lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Combined Modality The | 2004 |
Anaplastic large cell Ki-1 lymphoma: primary bone presentation in an elderly man.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Neoplasms; Chronic Disease; Cyclophosph | 1996 |
9 trials available for prednisone and Anaplastic Large-Cell Lymphoma
| Article | Year |
|---|---|
Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2.
Topics: Brentuximab Vedotin; Cyclophosphamide; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; | 2022 |
Long-term outcomes of adults with first-relapsed/refractory systemic anaplastic large-cell lymphoma in the pre-brentuximab vedotin era: A LYSA/SFGM-TC study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brentuxim | 2017 |
Advanced stage anaplastic large cell lymphoma in children and adolescents: results of ANHL0131, a randomized phase III trial of APO versus a modified regimen with vinblastine: a report from the children's oncology group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Doxorubi | 2014 |
Phase II trial of dose-adjusted EPOCH in untreated systemic anaplastic large cell lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival | 2016 |
Disseminated nonlymphoblastic lymphoma of childhood: a Childrens Cancer Group study, CCG-552.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Child, Preschoo | 1994 |
Anaplastic large-cell lymphoma: clinical and prognostic evaluation of 90 adult patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cyta | 1996 |
Subclassification of diffuse large B-cell lymphomas according to the Kiel classification: distinction of centroblastic and immunoblastic lymphomas is a significant prognostic risk factor.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Com | 1997 |
Anaplastic large cell lymphoma Hodgkin's-like: a randomized trial of ABVD versus MACOP-B with and without radiation therapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Ther | 1998 |
CD30(+) anaplastic large-cell lymphoma in children: analysis of 82 patients enrolled in two consecutive studies of the French Society of Pediatric Oncology.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bleomycin; Child; Chromosomes, Hu | 1998 |
65 other studies available for prednisone and Anaplastic Large-Cell Lymphoma
| Article | Year |
|---|---|
Impact of etoposide and ASCT on survival among patients aged <65 years with stage II to IV PTCL: a population-based cohort study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cyclophosphamide; Doxorubicin; Etopo | 2022 |
Outcome of limited-stage peripheral T-Cell lymphoma after CHOP(-like) therapy: A population based study of 239 patients from the Nordic lymphoma epidemiology group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Lympho | 2023 |
"Double-hit" of DUSP22 and TP63 rearrangements in anaplastic large cell lymphoma, ALK-negative.
Topics: Aged; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; | 2020 |
[Clinical characteristics and prognostic factors of 40 cases of primary systemic anaplastic large cell lymphoma].
Topics: Adolescent; Adult; Aged; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; | 2020 |
"Double hit" anaplastic large cell lymphoma with concurrent ALK and MYC rearrangements.
Topics: Adult; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; | 2020 |
Synchronous diagnosis of anaplastic large cell lymphoma and multiple myeloma in a patient: A case report.
Topics: Abdominal Wall; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Examination; | 2020 |
[Brentuximab vedotin for previously untreated systemic anaplastic large cell lymphoma].
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Brentuximab Ve | 2021 |
Anaplastic Large-Cell Lymphoma Associated with Breast Implants: A Case Report of a Transgender Female.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Implantation; Breast Implants | 2018 |
Breast Erythema in a Patient With Breast Implant-Associated Anaplastic Large Cell Lymphoma: A Case Report Discussing Cutaneous Manifestations.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Implantation; Breast Implants; | 2018 |
[Clinical features and prognosis for anaplastic large cell lymphoma].
Topics: Adolescent; Adult; Age Factors; Aged; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Pro | 2018 |
Anaplastic large cell lymphoma in a pregnant Filipino woman successfully treated with prepartum and postpartum chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans | 2018 |
Safety and effective salvage regimen comprising a novel combination of brentuximab vedotin, L-asparaginase, and dexamethasone for refractory anaplastic large cell lymphoma, anaplastic lymphoma kinase negative.
Topics: Aged; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bren | 2019 |
ALK-positive anaplastic large-cell lymphoma in adults: an individual patient data pooled analysis of 263 patients.
Topics: Adolescent; Adult; Aged; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; | 2019 |
Primary anaplastic large cell lymphoma in the dura of the brain: case report and prediction of a favorable prognosis.
Topics: Adult; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor | 2013 |
Anaplastic large cell lymphoma mimicking fibrosing mediastinitis.
Topics: Adult; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclop | 2013 |
Leukemic phase of ALK(+) anaplastic large-cell lymphoma, small-cell variant: clinicopathologic pitfalls of a rare entity.
Topics: Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow; Cyc | 2014 |
ALK-positive anaplastic large cell lymphoma with an unusual alveolar growth pattern.
Topics: Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biops | 2014 |
Cutaneous involvement in systemic anaplastic large cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diagnosis, Differential; Do | 2015 |
Anaplastic large-cell lymphoma presenting as a nasopharyngeal mass and cervical lymphadenopathy.
Topics: Airway Obstruction; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Cycl | 2015 |
Anaplastic large cell lymphoma with axial skeletal lesions portends a poor prognosis.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone | 2015 |
A case of Primary Bone Anaplastic Large Cell Lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; Doxorubicin; Femal | 2016 |
Anaplastic large cell lymphoma masquerading as osteomyelitis of the shoulder: an uncommon presentation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; Diagnosis, Differe | 2016 |
Successful use of the anti-CD25 antibody daclizumab in an adult patient with hemophagocytic lymphohistiocytosis.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2008 |
[Efficacy of therapy of different variants of anaplastic large T-cell lymphomas].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bleomycin; Cyclopho | 2008 |
Post transplant anaplastic large T-cell lymphoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Creatinine; Cyclophosphamide; | 2009 |
Anaplastic large cell lymphoma of the ovary in a pediatric patient.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modalit | 2009 |
Response: Intrathecal methotrexate and central nervous system events.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Disea | 2009 |
Small cell variant of anaplastic large cell lymphoma: a 10-year review of the All Wales Lymphoma Panel database.
Topics: Adolescent; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, | 2009 |
Fine needle aspiration cytology of ALK1(-), CD30+ anaplastic large cell lymphoma post renal transplantation: a case report and literature review.
Topics: Adult; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor | 2010 |
[Management of lymphoma with respect to pathologic classification: updates and controversies].
Topics: Anaplastic Lymphoma Kinase; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineopl | 2009 |
Cutaneous intravascular anaplastic large cell lymphoma.
Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blood Vessels; Cycl | 2011 |
Lymphoma of the breast capsule in a silicone implant-reconstructed patient.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Implantation; Breast Im | 2010 |
CD30-positive anaplastic variant diffuse large B cell lymphoma: a rare case presented with cutaneous involvement.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Ki-1 An | 2010 |
[Granulomatous slack skin with anaplastic large cell lymphoma: report of a case].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; CD2 Antigens; CD3 Complex; CD4 Antigens; Cycl | 2011 |
[CD30-negative and ALK-positive anaplastic large cell lymphoma: report of a case].
Topics: Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; CD2 Antigens; Child, Pre | 2011 |
The first Australian experience of heterotopic grafting of cryopreserved ovarian tissue: evidence of establishment of normal ovarian function.
Topics: Antineoplastic Combined Chemotherapy Protocols; Australia; Chorionic Gonadotropin, beta Subunit, Hum | 2011 |
Extended retreatment with brentuximab vedotin (SGN-35) maintains complete remission in patient with recurrent systemic anaplastic large-cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Carmustine; Clinical Tri | 2012 |
Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2012 |
Use of targeted therapy for refractory ALK-positive anaplastic large cell lymphoma as a bridging strategy prior to allogeneic transplantation.
Topics: Adult; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedot | 2013 |
Efficacy of peripheral blood stem cell transplantation versus conventional chemotherapy on anaplastic large-cell lymphoma:a retrospective study of 64 patients from a single center.
Topics: Adolescent; Adult; Age Factors; Aged; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemothera | 2012 |
[Clinicopathologic study of 20 cases of anaplastic large-cell lymphoma].
Topics: Adolescent; Adult; Aged; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; | 2012 |
Favorable outcome with doxorubicin-based chemotherapy and radiotherapy for adult patients with early stage primary systemic anaplastic large-cell lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 2013 |
Co-existent primary cutaneous anaplastic large cell lymphoma and lymphomatoid papulosis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Fem | 2003 |
[Anaplastic large cell lymphoma and keratoacanthoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Follow-Up Studi | 2004 |
KSHV/HHV8-associated lymphoma simulating anaplastic large cell lymphoma.
Topics: AIDS-Related Opportunistic Infections; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derive | 2004 |
Successful allogeneic stem cell transplantation for an adult with refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Doxorub | 2007 |
Disseminated strongyloidiasis and cytomegalovirus infection in a patient with anaplastic large cell lymphoma.
Topics: Adult; Albendazole; Anthelmintics; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; | 2007 |
Successful treatment for recurrence of primary cutaneous anaplastic large-cell lymphoma in elderly patient with etoposide, mitoxantrone, cyclophosphamide, vincristine, prednisolone and bleomycin (VNCOP-B) therapy.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxo | 2007 |
Multiple cutaneous relapses in an adolescent in anaplastic large cell lymphoma diagnosed by FNAC.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy, Fine-Needle; | 2008 |
Anaplastic large cell lymphoma (CD30 +/Ki-1+): results of a prospective clinico-pathological study of 69 cases.
Topics: Adolescent; Adult; Antigens, CD; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; | 1994 |
Ki-1-positive anaplastic large-cell lymphoma can mimic benign dermatoses.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cyclophosphamide; Diagnosis, Di | 1993 |
Childhood anaplastic large cell lymphoma Ki-1/CD30: clinicopathologic features of 19 cases.
Topics: Adolescent; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; | 1994 |
Supravenous hyperpigmentation in association with CHOP chemotherapy of a CD30 (Ki-1)-positive anaplastic large-cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Buttocks; Cyclophosphamide; Doxorubicin; Fore | 1995 |
Primary systemic CD30 (Ki-1)-positive anaplastic large cell lymphoma of the adult: sequential intensive treatment with the F-MACHOP regimen (+/- radiotherapy) and autologous bone marrow transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Comb | 1996 |
Regional enteritis complicating malignant lymphoma.
Topics: Adult; Aminosalicylic Acids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti | 1996 |
Clinicopathologic, cytogenetic, and molecular studies of 13 Chinese Patients with Ki-1 anaplastic large cell lymphoma. Special emphasis on the tumor response to 13-cis retinoic acid.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; China; Cyclophosphamide; Cytogenetics; Doxoru | 1996 |
Sequential intensive treatment with the F-MACHOP regimen (+/- radiotherapy) and autologous stem cell transplantation for primary systemic CD30 (Ki-1)--positive anaplastic large cell lymphoma in adults.
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosp | 1997 |
High serum levels of CA125 and interleukin-6 in a patient with Ki-1 lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Cyclophosphamide; Doxorubicin; | 1997 |
Primary CD30-positive anaplastic large cell lymphoma of the lip.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Lip Neoplasm | 1998 |
Downbeat nystagmus caused by thiamine deficiency: an unusual presentation of CNS localization of large cell anaplastic CD 30-positive non-Hodgkin's lymphoma.
Topics: Adult; Anisocoria; Antineoplastic Combined Chemotherapy Protocols; Aphasia; Bleomycin; Brain Neoplas | 1999 |
The therapy of primary adult systemic CD30-positive anaplastic large cell lymphoma: results of 40 cases treated in a single center.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dox | 1999 |
Neutrophil-rich anaplastic large cell lymphoma of T-cell lineage. A report of two cases arising in HIV-positive patients.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxo | 2000 |
Pathologic and clinical features of 77 Hodgkin's lymphoma patients treated in a lymphoma protocol (LNH87): a GELA study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarke | 2001 |
Primary cutaneous CD30 (Ki-1)-positive non-anaplastic B-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; DNA, Neoplasm; | 2002 |
Neutrophil-rich Ki-1-positive anaplastic large cell lymphoma: a study by fine-needle aspiration biopsy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma; Cyclophosphamide; | 2002 |